Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Advance Research in Neoepitopes, Cancer Vaccines and Immune Monitoring"
Deadline for manuscript submissions: closed (31 May 2019).
2. Department of Biochemistry and Molecular Biology, University of Miami Leonard M. Miller School of Medicine, Miami, United States
Interests: cancer vaccine; neoantigens; personalized medicine; adjuvants; nanocarriers; peptide-MHC; MHC Tetramers; nucleic acid based-vaccines
The cancer immunology stage has never been this equipped for cancer vaccines. Neoantigen discovery and validation has been advancing expeditiously. The first wave of neoantigen-based vaccine discoveries has been very exciting in a personalized nature, which seem to be further promising based on new reports on public neoantigens. To this end, the development of nucleic-based cancer vaccines encoding for the neoepitopes, and later their novel nanocarriers, with positive preclinical data, have gotten closer to being injected into humans. Moreover, peptide-MHC-based cancer vaccines or their biosimilars and those that are bi-specific, carrying other immunomodulatory moieties, are being designed and tested, adding to the excitement of modern cancer vaccines. More importantly, only a fraction of cancer patients benefits from immune checkpoint blockades (ICBs), those that have intrinsic tumor specific T cell responses. Cancer vaccines are perhaps the best practical approach to elicit anti-tumor responses in naïve hosts. This Special Issue will include original research, review articles, commentaries, and editorials discussing the design, use, and immunomonitoring of various types of cancer vaccines. Topics of interest for this Special Issue include, but are not limited to, the keywords listed below.
Dr. Pirouz Daftarian
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Cancer vaccine
- personalized medicine
- MHC Tetramers
- nucleic acid based-vaccines
- immune monitoring of vaccines
- nucleic acid-based vaccines
- Dendritic based cancer vaccines
- tumor specific antigens
- public neoantigens